Plasma Protein Therapeutics Market Report 2025

The plasma protein therapeutics market size has grown strongly in recent years. It will grow from $31.86 billion in 2024 to $34.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of rare diseases, growing aging population, global blood plasma supply, rise in hemophilia cases, improvements in diagnosis, supportive regulatory environment.

The plasma protein therapeutics market size is expected to see strong growth in the next few years. It will grow to $46.35 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to gene therapy advancements, increasing healthcare expenditure, expanded indications, precision medicine approaches, patient access programs. Major trends in the forecast period include technological innovations, telemedicine adoption, technological advancements in plasma fractionation, development of next-generation therapies, adoption of recombinant therapies, personalized medicine approaches.

The rising prevalence of autoimmune disorders is anticipated to drive the growth of the plasma protein therapeutics market in the future. Autoimmune disorders occur when the body's immune system mistakenly attacks and destroys healthy cells. Therapeutic plasma exchange is a treatment used for these diseases, wherein the body incorrectly identifies part of itself as foreign and produces proteins called autoantibodies that target these misidentified areas. For instance, in May 2023, a study conducted by the University of Glasgow, a public university in the UK, involving 22 million people, revealed that autoimmune disorders affect approximately 10% of the UK population, surpassing previous estimates. Thus, the increasing incidence of autoimmune disorders is propelling the growth of the plasma protein therapeutics market moving forward.

The growth of the plasma protein therapeutics market is expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting a year or longer and requiring ongoing medical care, significantly impact daily activities. Plasma protein therapeutics play a crucial role in managing chronic diseases by addressing deficiencies, modulating the immune system, and providing support for various physiological functions. According to the World Health Organization's data from September 2022, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million deaths globally each year. Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this statistic. Therefore, the growing prevalence of chronic diseases is driving the growth of the plasma protein therapeutics market.

Product innovations are emerging as a significant trend in the plasma protein therapeutics market. Major companies in this sector are concentrating on developing innovative products to secure a competitive edge. For example, in October 2023, Octapharma AG, a Switzerland-based company, received approval from European medical authorities for the lyophilized version of its well-known product, octaplasLG. This advanced formulation is intended for pre-hospital transfusions, offering healthcare professionals a convenient and effective option for managing patients in critical conditions. This approval highlights Octapharma's dedication to improving patient care through innovative solutions in the blood products arena.

Strategic collaborations are playing a crucial role in the plasma protein therapeutics market. Major companies are entering partnerships to enhance their product portfolios, extend global reach, and drive innovation in new therapy development. For instance, LFB Plasma, a US-based plasma collection company, announced a collaboration with the Plasma Protein Therapeutics Association (PPTA) in September 2022. This strategic partnership is aimed at expanding LFB Plasma's presence in the US and reinforcing its commitment to both plasma donors and patients.

In April 2022, Grifols S.A., a Spain-based pharmaceutical and chemical manufacturer, acquired Tiancheng (Germany) Pharmaceutical Holdings AG for €1.6 billion ($1.72 billion). This acquisition is expected to accelerate and broaden Grifols' product portfolio, increase patient access to plasma therapies, and drive revenue growth and margin expansion. Tiancheng (Germany) Pharmaceutical Holdings AG, also known as Biotest, is a Germany-based healthcare company specializing in innovative hematology and clinical immunology, focusing on the development, manufacturing, and marketing of plasma proteins and biotherapeutic drugs.

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood.

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plasma protein therapeutics involves treatments derived from plasma and their recombinant counterparts, designed to address specific medical conditions by replacing deficient or missing proteins present in plasma. This enables recipients to lead healthier and more productive lives.

The primary products within plasma protein therapeutics include immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other related products. Immunoglobulin constitutes a component of blood plasma containing antibodies, and it is administered through various routes such as intravenous and subcutaneous. These treatments find applications in addressing conditions such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and various other medical needs.

The plasma protein therapeutics market research report is one of a series of new reports that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.